Pfäffikon SZ - BioMarin Pharmaceutical is joining forces with DiNAQOR from the Greater Zurich Area. Together, the new partners are planning to develop new treatments for rare myocardial disorders. To this end, BioMarin has additionally licensed a therapy from DiNAQOR that is currently still under development.

The US biotech firm BioMarin Pharmaceutical has agreed a cooperation with DiNAQOR AG based in Pfäffikon. The aim here is to develop new treatments for rare, genetic myocardial disorders. Within the framework of this partnership, BioMarin has also acquired a license for the preclinical program DiNA-001 from DiNAQOR. This focuses on the gene MYBPC3, a mutation of which plays a decisive role in certain myocardial diseases.

According to a press release, DiNAQOR will receive an upfront payment in an undisclosed amount. Moreover, milestone payments in recognition of major successes in addition to multi-tiered royalty payments on product sales have been included in the agreement.

DiNAQOR was founded in 2019 by a group of several biotech and pharma experts. In addition to the headquarters in Pfäffikon, the company also maintains a presence in the USA and the UK. DiNA-001 is the company’s leading therapy candidate.

Related news

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?  
info@greaterzuricharea.com